Related references
Note: Only part of the references are listed.Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group
Cindy L. Schwartz et al.
PEDIATRIC BLOOD & CANCER (2016)
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Michael S. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment
J. S. Whelan et al.
ANNALS OF ONCOLOGY (2015)
SATB2 enhances migration and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization
B. K. A. Seong et al.
ONCOGENE (2015)
The Role of SATB2 as a Diagnostic Marker for Tumors of Colorectal Origin
Anca Dragomir et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2014)
Primary Sclerosing Epithelioid Fibrosarcoma of Bone
John B. Wojcik et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Cadherin-17 and SATB2 Are Sensitive and Specific Immunomarkers for Medullary Carcinoma of the Large Intestine
Fan Lin et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
An approach to pleomorphic sarcomas: can we subclassify, and does it matter?
John R. Goldblum
MODERN PATHOLOGY (2014)
SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours
James R. Conner et al.
HISTOPATHOLOGY (2013)
Effects of a miR-31, Runx2, and Satb2 Regulatory Loop on the Osteogenic Differentiation of Bone Mesenchymal Stem Cells
Yuan Deng et al.
STEM CELLS AND DEVELOPMENT (2013)
Regulators of skeletal development: a cluster analysis of 206 bone tumors reveals diagnostically useful markers
Andrew E. Horvai et al.
MODERN PATHOLOGY (2012)
Decreased Expression of SATB2: A Novel Independent Prognostic Marker of Worse Outcome in Laryngeal Carcinoma Patients
Tian-Run Liu et al.
PLOS ONE (2012)
Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches
Salvatore Romeo et al.
VIRCHOWS ARCHIV (2012)
SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas
Kristina Magnusson et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. C. W. Hogendoorn et al.
ANNALS OF ONCOLOGY (2010)
A Cross-Species Analysis of Satb2 Expression Suggests Deep Conservation Across Vertebrate Lineages
Kelly Sheehan-Rooney et al.
DEVELOPMENTAL DYNAMICS (2010)
SATB2 augments ΔNp63α in head and neck squamous cell carcinoma
Jacky Chung et al.
EMBO REPORTS (2010)
A network connecting Runx2, SATB2, and the miR-23a∼27a∼24-2 cluster regulates the osteoblast differentiation program
Mohammad Q. Hassan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH
S. Selvarajah et al.
CYTOGENETIC AND GENOME RESEARCH (2008)
Heterozygous nonsense mutation SATB2 associated with cleft palate, osteoporosis, and cognitive defects
Petcharat Leoyklang et al.
HUMAN MUTATION (2007)
SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation
Gergana Dobreva et al.
CELL (2006)
Classification of pleomorphic sarcomas: where are we now?
APD Tos
HISTOPATHOLOGY (2006)
Biology and therapeutic advances for pediatric osteosarcoma
N Marina et al.
ONCOLOGIST (2004)
Identification of SATB2 as the cleft palate gene on 2q32-q33
DR FitzPatrick et al.
HUMAN MOLECULAR GENETICS (2003)
Share Paper
